Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma

References

• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health. National Heart, Lung and Blood Institute 2002; Publication No. 02–3659
   Google Scholar
• Asthma UK. Where do we stand? Asthma in the UK today 2004
   Google Scholar
• Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination. Pharmacoeconomics 2003;21:951–89
   PubMed Web of Science ®Google Scholar
• National Asthma Campaign. Out in the open. A picture of asthma in the UK today 2002
   Google Scholar
• Hoskins G, McCowan C, Neville R, et al. Risk factors and costs associated with an asthma attack. PharmacoEconomics and Outcomes News 2000;253:8
   Google Scholar
• Vervloet D, Williams A, Lloyd A, Clark T. Costs of managing asthma as defined by a derived Asthma Control TestTM score in seven European countries. Eur Respir Rev 2006;15:17–23
   Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22–27
   Google Scholar
• British Thoracic Society. British Guideline on the Management of Asthma. Revised edn. November, 2005
   Google Scholar
• Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. J Allergy Clin Immunol 2001;108:39–46
   PubMed Web of Science ®Google Scholar
• Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002;20:183–94
   PubMed Web of Science ®Google Scholar
• Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. The Cochrane Database Syst Rev 2005; Issue 3: CD002310.pub3. DOI:10.1002/14651858.CD002310.pub3
   Google Scholar
• Ni Chroinin M, Greenstone I, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev (Online: Update Software) 2007;1
   Google Scholar
• Bateman ED, Silins V, Bogolubov M. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 mg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. Respir Med 2001;95:136–46 (SFCB3022)
   Google Scholar
• van Noord JA, Lill H, Carillo Diaz T, et al. Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500 mcg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus in patients with moderate to severe asthma. Clin Drug Invest 2001;21:243–55 (SFCB3023)
   Google Scholar
• Bateman ED, Bousehey H, Bousquet J, et al. Can Guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004;170:836–44 (SAM40027)
   Google Scholar
• Hornik K. The R FAQ. http://CRAN.R-project.org/doc/FAQ/RFAQ.html (accessed July 2006) ISBN 3–900051–08–9 2006
   Google Scholar
• GSK. Clinical Trials Register. http://ctr.gsk.co.uk/Summary/fluticasone_salmeterol/studylist.asp (accessed 30 April 2006) 2006
   Google Scholar
• Aalbers R, Backer V, Kava T, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20:225–40
   PubMed Web of Science ®Google Scholar
• Fitzgerald J, Boulet L, Follows R. The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005;27: 393–406
   Google Scholar
• Vogelmeier C, D’Urzo A, Pauwels R, et al. Budesonide/ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819–28
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Clinical Excellence. Technology Appraisal Guidance No 10. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. http://www.nice.org.uk/download.aspx?o=TA010guidance&template=download.aspx (accessed July 2006) 2000
   Google Scholar
• National Institute of Health and Clinical Excellence. Technology Appraisal Guidance No 38. Inhaler devices for routine treatment of asthma in older children (aged 5–15 years). http://www.nice.org.uk/page.aspx?o=TA038guidance (accessed July 2006) 2002
   Google Scholar
• Drug Tariff. http://www.drugtariff.com (accessed July 2006)
   Google Scholar
• eMIMS. http://www.emims.net (accessed July 2006) 2006
   Google Scholar
• Briggs AH, Bousquet J, Wallace MV, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531–6
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference based condition-specific instruments: Converting AQLQ into EQ5D indices. Discussion paper 02/1 http://www.shef.ac.uk/content/1/c6/01/87/47/DP0201.pdf (accessed July 2006) 2002
   Google Scholar
• Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996;9:120
   Web of Science ®Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779–87
   Google Scholar
• National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. April 2004
   Google Scholar
• Higgins J, Green S (editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons Ltd
   Google Scholar
• Bjermer L. Evidence-based recommendations or ‘show me the patients selected and I will tell you the results’. Respir Med 2006;100 Suppl. A:S17–21. Epub 2006 May 23
   Google Scholar
• Herland K, Akelsen J, Skjønsberg, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger ‘real life’ population of patients with obstructive lung disease? Respir Med 2005;99:11–19
   Google Scholar
• Chipps J, Spahn C, Sorkness L, et al. Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting β2-agonists. J Pediatr 2006;148:517–21B
   Google Scholar
• Stempel DA, Stoloff SW, Carranza R, Jr., et al. Adherence to asthma controller medication regimens. Respir Med 2005;99:1263–7
   PubMed Web of Science ®Google Scholar
• Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245–51
   PubMed Web of Science ®Google Scholar
• Tews JT, Volmer T. Differences in compliance between combined salmeterol/fluticasone propionate in the Diskus device and fluticasone + salmeterol given via separate Diskus inhalers. Am J Respir Crit Care Med 2002;165:A188
   Google Scholar
• Marceau C, Lemiere C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006;118: 574–81
   PubMed Web of Science ®Google Scholar
• O’Connor RD, Carranza Rosenzweig J, Stanford R, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol 2005;95: 535–40
   Google Scholar
• Delea TE, Hagiwara M, Stanford R, Stempel DA. Utilization and costs of asthma-related care in patients initiating fluticasone propionate/salmeterol combination, salmeterol, or montelukast as add-on therapy to inhaled corticosteroids. Data in preparation 2006
   Google Scholar
• MHRA. Commission on Human Medicines. Salmeterol (Serevent) and formoterol (Oxis, Foradil) in asthma management. Curr Probl Pharmacovigilance 2006;31:6
   Google Scholar
• Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003;112:29–36
   PubMed Web of Science ®Google Scholar
• Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/ fluticasone propionate (50/250 microg) combination is superior to double dose fluticsone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 2004;134:50–8 (SAS40009)
   Google Scholar
• Bateman ED, Britton M, Carillo J, et al. Salmeterol/fluticasone propionate (50/100 mg) combination inhaler (Seretide). A new effective and well tolerated treatment for asthma. Clin Drug Invest 1998;16:193–201 (SFCB3017)
   Google Scholar
• Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 mg) administered via combination Diskus inhaler: As effective as when given via s eparate Diskus inhalers. Can Respir J 1999;6:45–51 (SFCB3018)
   Google Scholar
• Aubier M, Pieters WT, Schlosser NJJ, et al. Salmeterol/ fluticasone propionate (50/500 mcg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93:876–84 (SFCB3019)
   Google Scholar
• Dahl R, Chuchalin A, Gor D, et al. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/ budesonide combinations in adults with persistent asthma. Respir Med 2006;100:1152–62 (SAM40040)
   Google Scholar
• Van den Berg NJ, Ossip MS, Hederos CA, et al. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Ped Pulm 2000;30:97–105 (SFCB3020)
   Google Scholar
• Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Personal and Social Services Research Unit, University of Kent. Available at htp://pssru.ac.uk/publications.htm (Accessed July 2006)
   Google Scholar
• NHS Reference Costs. http://www.dh.gov.uk/assetRoot/04/10/55/61/04105561.xls. (accessed July 2006) 2004
   Google Scholar